Pricing Log in Create free account
Monday 9 November 2026 Export PLX’s income statement to Excel — free account

Protalix BioTherapeutics, Inc.

PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.

Revenue
+27.1%
EPS
+2,281.0%
Free cash flow
−94.1%

Quarter to June 2026, against a year earlier

2.54 0.03 +1.20%
Market cap
$204.7M
P/E
10.5×
Fwd P/E
10.6×
Dividend yield
—
F-score
3/9
ROIC
48.5%
Net debt / EBITDA
7.7×
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Net bought
$101.4K
Trades
0 sells · 1 buy
Ownership
8.37%

Capital & Financial Ratios $m

Size
Market Cap 205
Revenue ttm 81
Net income ttm 19
Free cash flow ttm 8
Net debt Q (41)
Valuation
P/E 10.5
Forward P/E 10.6
Price / sales 2.5
Forward P/S Powerpack
Price / FCF 26.3
Price / book 2.8
Financial health
Current ratio Q 2.9 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth Q +27.1% (above 0%: growing)
Operating income growth Q +298.6% (above 0%: growing)
EPS, this year +400.0% (at or above 15%: strong)
EPS, next year A −79.2% (below 0%: weak)
Revenue, next year A +30.2% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +110.6% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 2.1×; over the ten years it ranged from −0.1× in 2021 to 26.6× in 2016.
P/E against its own 10 years 44.10%
10-year low 10-year high
P/S against its own 10 years 61.33%
10-year low 10-year high
P/B against its own 10 years 29.18%
10-year low 10-year high
EV/Sales against its own 10 years 57.87%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 45 35 31 41
Receivables 5 3 9 17
Inventory 19 21 26 32
Other 1 1 1 2
70 60 67 92
2023 2024 2025 Q'26
Payables 24 24 25 30
ST’ Debt — — — —
Other — — — —
46 26 27 31

Compound Annual Growth %

10y 5y 3y
Sales 28.30% (3.46%) 3.45%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 16.06% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.01 Actual 0.05

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.06 0.03 Miss by 0.03
Q4 FY25 0.01 −0.07 Miss by 0.08
Q1 FY26 −0.01 0.22 Beat by 0.23
Q2 FY26 −0.01 0.05 Beat by 0.06
Q3 FY26 −0.02 — Reports 10 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.22 0.05 — — —
’25 (0.05) 0.00 0.03 (0.07) (0.08)
’24 (0.06) (0.03) 0.03 0.09 0.04
’23 (0.05) 0.21 (0.02) (0.07) 0.09
’22 (0.05) (0.11) (0.07) (0.07) (0.31)
’21 (0.14) (0.25) (0.09) (0.14) (0.62)
’20 0.10 (0.13) (0.14) 0.03 (0.22)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 34 20 — — —
’25 10 16 18 9 53
’24 4 13 18 18 53
’23 10 35 10 10 65
’22 16 9 14 9 48
’21 11 6 12 9 38
’20 22 11 11 19 63
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 22 (10) — — —
’25 (5) (5) (4) 2 (12)
’24 4 (4) 4 4 9
’23 (3) 5 (7) 4 (1)
’22 (6) (7) (9) (3) (25)
’21 (10) 7 (2) (5) (10)
’20 (7) (8) (4) (8) (26)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 21 (11) — — —
’25 (5) (6) (4) 2 (14)
’24 4 (4) 4 4 7
’23 (3) 5 (7) 3 (2)
’22 (6) (7) (9) (3) (26)
’21 (10) 6 (2) (6) (12)
’20 (7) (8) (4) (8) (27)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 9 21 34 55 63 38 48 65 53 53 81 +21.4% 69 65 69 +9.3%
Gross margin, % 8.71 27.74 72.83 80.08 82.71 57.37 58.87 64.91 54.46 48.82 69.20 +40.1 pt
EBT (29) (83) (26) (18) (7) (28) (14) 9 4 (6) 23 (16.7%)
EBT margin, % (317.16) (395.86) (77.27) (33.42) (10.37) (71.92) (30.22) 13.08 7.78 (10.63) 29.10 +306.5 pt
Net income (29) (83) (26) (18) (7) (28) (15) 8 3 (7) 19 (15.3%)
Per share, $
Per share, $ Revenue 0.91 1.61 2.33 3.69 2.16 0.87 0.98 0.97 0.74 0.67 1.01 (3.3%)
Earnings (2.90) (6.50) (1.80) (1.23) (0.22) (0.62) (0.31) 0.12 0.04 (0.08) 0.24 (32.9%)
Cash flow (3.17) (0.76) (0.53) (1.30) (0.90) (0.23) (0.52) (0.02) 0.12 (0.15) 0.12 (28.6%)
Capex (0.08) (0.07) (0.05) (0.04) (0.02) (0.03) (0.01) (0.02) (0.02) (0.02) (0.03) (14.1%)
Free cash flow (3.25) (0.84) (0.57) (1.35) (0.92) (0.26) (0.53) (0.04) 0.10 (0.17) 0.10 (27.8%)
Book value (0.98) (2.25) (3.59) (4.74) (0.93) (0.14) (0.22) 0.50 0.60 0.61 0.89 n/m
Shares, m 10 13 15 15 29 44 48 68 73 79 79 +25.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.00 47.00 0.00 10.50 6.1
P/S 4.57 4.32 1.34 0.89 1.68 0.96 1.39 1.88 2.55 2.68 2.50 2.2
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.66 3.16 2.93 2.82 1.0
EV/Sales (0.20) 4.08 1.63 1.50 1.14 0.67 1.52 1.50 2.28 2.48 2.24 1.7
EV/FCF 0.06 (7.85) (6.63) (4.09) (2.68) (2.18) (2.83) (39.90) 16.45 (9.58) 23.52 (5.9)
Cash, $m
Cash, $m Operating cash flow (32) (10) (8) (19) (26) (10) (25) (1) 9 (12) 10 (10.4%)
Capex (1) (1) (1) (1) (1) (1) (1) (1) (1) (2) (2) +7.9%
Free cash flow (33) (11) (8) (20) (27) (12) (26) (2) 7 (14) 8 (9.3%)
Balance, $m
Balance, $m Working capital 6 40 28 (8) (31) 28 12 24 34 40 61 +24.3%
Net debt (44) (5) 10 33 (34) (11) 6 (45) (35) (31) (41) (3.8%)
Shareholders’ equity (10) (29) (53) (70) (27) (6) (11) 34 43 48 71 n/m
Returns, %
Returns, % ROA (32.72) (108.04) (39.68) (34.31) (11.51) (38.96) (23.06) 11.86 3.71 (8.48) 20.07 +24.2 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.21 (19.92) 48.48 (19.9) pt
ROE (6,411.57) 423.40 64.26 29.67 13.40 166.79 179.02 72.50 7.64 (14.44) 31.23 +6,397.1 pt
People
People Employees 232 190 184 196 207 206 197 208 213 226 — (0.3%)
Revenue/emp, $m 0.04 0.11 0.19 0.28 0.30 0.19 0.24 0.31 0.25 0.23 — +21.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Protalix BioTherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLGL Sol-Gel Technologies Ltd. $206.3M — (loss-making) — (loss-making) −96.58% (below 0%: shrinking) n/m −8.76% (below 0%: shrinking) 100.00% (704.23%) Compare
RNAC Cartesian Therapeutics, Inc. $205.1M — (loss-making) — (loss-making) −92.91% (below 0%: shrinking) −7.84% (below 0%: shrinking) −6.15% (below 0%: shrinking) 100.00% 0.00% Compare
DRUG Bright Minds Biosciences Inc. $204.2M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
PLX Protalix BioTherapeutics, Inc. $202.2M 10.5× 10.6× +27.07% (above 0%: growing) +2,280.95% (above 0%: growing) −94.09% (below 0%: shrinking) 60.99% 23.48%
PALI Palisade Bio, Inc. $202.2M 1.8× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ARTV Artiva Biotherapeutics, Inc. $201.9M — (loss-making) — (loss-making) — n/m +13.60% (above 0%: growing) 100.00% 0.00% Compare
IKT Inhibikase Therapeutics, Inc. $200.9M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −123.23% (below 0%: shrinking) 0.00% 0.00% Compare
ELDN Eledon Pharmaceuticals, Inc. $199.9M — (loss-making) — — n/m −28.02% (below 0%: shrinking) 0.00% 0.00% Compare
IFRX InflaRx N.V. $199.7M — (loss-making) — (loss-making) −128.93% (below 0%: shrinking) n/m +59.76% (above 0%: growing) 14,029.95% 0.00% Compare
Median of peers $202.0M — — −96.58% — −18.39% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.17m 1.52m 95.74
2024 1.53m 524.66k 105.62
2023 2.68m 3.19m 129.93

Ownership

Directors and executive officers, together 6.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Protalix BioTherapeutics, Inc. (PLX) Latest News

13 Aug

Impact 3 · · Moby transcript
Impact 3 ·

12 Aug

Impact 3 · transcript

14 May

Impact 4 · · Zacks Small Cap Research

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · Benzinga transcript
Impact 3 · · Moby
Impact 3 · · PR Newswire

18 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Zacks Small Cap Research
Impact 4 · · Proactive Investors
Impact 4 ·
Impact 4 · · PR Newswire

9 Mar

Impact 4 · · Proactive Investors
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

9 Feb

Impact 3 · · Simply Wall St.

3 Feb

Impact 4 · · Zacks Small Cap ResearchMT NewswiresMotley FoolMotley FoolPharmaceutical TechnologyMotley FoolPharmaceutical TechnologyPharmaceutical Technology

30 Jan

Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

5 Jan

Impact 3 · · PR NewswireMT NewswiresSimply Wall St.Simply Wall St.AFPSimply Wall St.Simply Wall St.Simply Wall St.

22 Dec

Impact 4 · · Zacks Small Cap Research

17 Dec

Impact 3 ·

17 Nov

Impact 4 · · Zacks Small Cap Research

14 Nov

Impact 4 · · Moby

13 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · Associated Press Finance
Impact 3 · · PR Newswire

3 Nov

Impact 4 · · GlobeNewswire

27 Oct

Impact 3 ·
stockrow.com/PLX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com